Synopsis of KCNT1 programs in 2022.

UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.

Treatment of KCNT1 mutant mouse models show improvements in behavior and reduced seizures.

We are grateful to have the support of three interns this summer: Jacqueline Fung, Michaela Taylor, Astrid Torres!

Co-founder, Justin West participates in a panel of rare dads who are working to make a difference.

Foundation Executive Director visits labs to learn about the KCNT1 cell models they are developing.

Today, the KCNT1 Epilepsy Foundation is proud to announce that we have launched a Digital Natural History Study (NHS) in partnership with Invitae. Our goal in establishing this leading-edge program utilizing Invitae’s Ciitizen technology is to accelerate the analysis of patient data for rare disease drug development -- and, in particular, to find treatments and cures for KCNT1. Click to read the press release.

Co-founder Justin West was interviewed for Rare disease week, where he shares his story and determination to find treatments for all the children with KCNT1 related illnesses.

Co-founder Samantha MacMechan interviewed on Good Day Chicago Fox 32 about KCNT1 diagnosis and fighting for a cure .

Co-Founder, Justin West and his family are featured in a local magazine for Rare Disease Week.

Dr. Justin West, an Orange County plastic surgeon, describes his 3-year-old son’s genetic seizure disorder and the search for treatment.

In this episode we hear from Samantha MacMechan, Co-Founder of the KCNT1 Epilepsy Foundation, sharing on their nonprofit’s awesome mission to find a disease-modifying treatment for their incredible kiddo warriors.

Program incorporates patient-driven study to inform research and drug development for KCNT1-related epilepsy